CognitiveResearch Phase

Orexin A

Intracerebroventricular

Overview

Orexin A is a 33-amino acid neuropeptide produced in the lateral hypothalamus that plays a critical role in the regulation of wakefulness, arousal, and energy homeostasis. It binds with high affinity to both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R), promoting cortical activation and stabilizing the wake state.

Mechanism of Action

Deficiency of orexin signaling is the hallmark of narcolepsy type 1, making orexin replacement a rational therapeutic strategy..

Research Summary & Key Findings

Preclinical studies in narcoleptic animal models have demonstrated that central administration of orexin A restores wakefulness and reduces cataplexy, with findings published in leading neuroscience journals in the early 2000s. Therapeutic development has been hindered by poor blood-brain barrier penetration and peptide instability, prompting focus on orexin receptor agonists rather than peptide replacement. No orexin A formulation has advanced to clinical trials in humans.

Clinical Status

Research Phase

Orexin A is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intracerebroventricular

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Orexin A therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Orexin A.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.